ID   GP38_BPLP0              Reviewed;          71 AA.
AC   Q09YD1;
DT   29-APR-2015, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 1.
DT   23-FEB-2022, entry version 27.
DE   RecName: Full=Gene product 38 {ECO:0000305};
DE            Short=gp38;
DE   AltName: Full=AbiQ resistance protein {ECO:0000305};
DE   AltName: Full=ORF38 {ECO:0000303|PubMed:23813728};
GN   ORFNames=orf38 {ECO:0000303|PubMed:23813728};
OS   Lactococcus phage P008.
OC   Viruses; Duplodnaviria; Heunggongvirae; Uroviricota; Caudoviricetes;
OC   Caudovirales; Siphoviridae; Skunavirus.
OX   NCBI_TaxID=83129;
OH   NCBI_TaxID=272623; Lactococcus lactis subsp. lactis (strain IL1403) (Streptococcus lactis).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=16907729; DOI=10.1111/j.1574-6968.2006.00372.x;
RA   Mahony J., Deveau H., Mc Grath S., Ventura M., Canchaya C., Moineau S.,
RA   Fitzgerald G.F., van Sinderen D.;
RT   "Sequence and comparative genomic analysis of lactococcal bacteriophages
RT   jj50, 712 and P008: evolutionary insights into the 936 phage species.";
RL   FEMS Microbiol. Lett. 261:253-261(2006).
RN   [2]
RP   FUNCTION, IDENTIFICATION BY MASS SPECTROMETRY, INDUCTION, DISRUPTION
RP   PHENOTYPE, POLYMORPHISM, VARIANTS ILE-3; GLY-6; ASN-18; GLY-23;
RP   30-TRP--ASN-71; LEU-38 AND PRO-49, AND CHARACTERIZATION OF VARIANTS ILE-3;
RP   GLY-6; ASN-18; GLY-23; 30-TRP--ASN-71; LEU-38 AND PRO-49.
RX   PubMed=23813728; DOI=10.1128/jb.00296-13;
RA   Samson J.E., Belanger M., Moineau S.;
RT   "Effect of the abortive infection mechanism and type III toxin/antitoxin
RT   system AbiQ on the lytic cycle of Lactococcus lactis phages.";
RL   J. Bacteriol. 195:3947-3956(2013).
CC   -!- FUNCTION: Involved in escape from killing mediated by the bacterial
CC       AbiQ protein upon infection of L.lactis subsp. lactis strain IL1403. 11
CC       distinct mutations in the protein and 2 in the ribosome-binding site
CC       confer on the virus the ability to partially escape killing (i.e. the
CC       virus grows in the bacteria), in some cases probably by decreasing the
CC       protein level. At least one of these variants (Leu-38) has reduced
CC       fitness compared to the wild-type strain.
CC       {ECO:0000305|PubMed:23813728}.
CC   -!- INDUCTION: Expressed early in the viral replication cycle (at protein
CC       level). Transcript is detected 2 minutes after infection, peaks at 10
CC       minutes and is degraded to a smaller size by 20 minutes. Some smaller
CC       transcripts were detected in bacteria expressing AbiQ (AC Q9ZJ19).
CC       {ECO:0000269|PubMed:23813728}.
CC   -!- POLYMORPHISM: Variant P008-Q1, mutation of the ATG start codon to TTG
CC       encoding Leu (a less efficient start codon in the host L.lactis),
CC       confers partial resistance to bacterial AbiQ. A silent mutation in
CC       variant P008-Q5 of one Thr codon to another (ACA to ACC, ACC is half as
CC       frequent in the virus and thus probably less efficiently translated)
CC       also confers partial resistance to bacterial AbiQ.
CC       {ECO:0000269|PubMed:23813728}.
CC   -!- DISRUPTION PHENOTYPE: Cannot be generated, suggesting it is essential
CC       for virus function. {ECO:0000269|PubMed:23813728}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; DQ054536; AAY97840.1; -; Genomic_DNA.
DR   RefSeq; YP_762549.1; NC_008363.1.
DR   SMR; Q09YD1; -.
DR   GeneID; 5141185; -.
DR   KEGG; vg:5141185; -.
DR   Proteomes; UP000000910; Genome.
PE   1: Evidence at protein level;
KW   Early protein; Reference proteome.
FT   CHAIN           1..71
FT                   /note="Gene product 38"
FT                   /id="PRO_0000432938"
FT   VARIANT         3
FT                   /note="T -> I (in P008H2-10; confers partial resistance to
FT                   bacterial AbiQ)"
FT                   /evidence="ECO:0000269|PubMed:23813728"
FT   VARIANT         6
FT                   /note="E -> G (in P008H2-7; confers partial resistance to
FT                   bacterial AbiQ)"
FT                   /evidence="ECO:0000269|PubMed:23813728"
FT   VARIANT         18
FT                   /note="S -> N (in P008-Q4; confers partial resistance to
FT                   bacterial AbiQ)"
FT                   /evidence="ECO:0000269|PubMed:23813728"
FT   VARIANT         23
FT                   /note="D -> G (in P008-Q16; confers partial resistance to
FT                   bacterial AbiQ)"
FT                   /evidence="ECO:0000269|PubMed:23813728"
FT   VARIANT         30..71
FT                   /note="Missing (in P008-Q19; confers partial resistance to
FT                   bacterial AbiQ)"
FT                   /evidence="ECO:0000269|PubMed:23813728"
FT   VARIANT         38
FT                   /note="P -> L (in P008-Q12; confers partial resistance to
FT                   bacterial AbiQ, altered expression profile of virus gene
FT                   orf53, reduced virus burst size, longer lytic cycle, i.e.
FT                   reduced fitness)"
FT                   /evidence="ECO:0000269|PubMed:23813728"
FT   VARIANT         49
FT                   /note="S -> P (in P008-Q11; confers partial resistance to
FT                   bacterial AbiQ)"
FT                   /evidence="ECO:0000269|PubMed:23813728"
SQ   SEQUENCE   71 AA;  8306 MW;  77B9606D6E8368DA CRC64;
     MYTAEEREQI IDIVDKMSLL RQDFDGAFTW IKENVAMPFD FDGEQQFISD LKQLVKINAL
     KFGKIYEGVL N